AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Emmanuel S. Antonarakis, Changxue Lu, Hao Wang, +17

New England Journal of Medicine

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, +8

JAMA Oncology

PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer

Steven P. Rowe, Katarzyna J. Macura, Esther Mena, +12

Molecular Imaging and Biology

Positron Emission TomographyMetastatic Prostate CancerUrologyImaging BiomarkersLesion Detection +11

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Andrea B. Apolo, Rosa Nadal, Daniel M. Girardi, +32

Journal of Clinical Oncology

Comparison of Prostate-Specific Membrane Antigen–Based ¹⁸F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer

Steven P. Rowe, Katarzyna J. Macura, Anthony Ciarallo, +13

Journal of Nuclear Medicine

Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone

Daniel L. Suzman, Brandon Luber, Michael T. Schweizer, +2

The Prostate

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Andrea B. Apolo, Rosa Nadal, Yusuke Tomita, +29

The Lancet Oncology

UrologyGenitourinary CancerMedicineClinical TrialsImmune Checkpoint Inhibitor +6

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Heather H. Cheng, Roman Gulati, Arun Azad, +14

Prostate Cancer and Prostatic Diseases

Medicinal ChemistryUrologyOncologyAbiraterone And/or DocetaxelMedicine +5

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study

Michael T. Schweizer, Hao Wang, Brandon Luber, +9

The Prostate

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

Rosa Nadal, A. Amin, Daniel M. Geynisman, +10

Annals of Oncology

UrologyGenitourinary CancerMedicineCell Death 1Kinase Inhibitors +4